Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 95-102

  Tolcher, A W ^a   Cowan, K H ^a   Noone, M H ^a   Denicoff, A M ^a   Kohler, D R ^a   Goldspiel, B R ^a   Barnes, C S ^a   McCabe, M ^a   Gossard, M R ^a   Zujewski, J ^a   O'Shaughnessy, J A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; MESNA; MITOXANTRONE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPERSENSITIVITY REACTION; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; OUTPATIENT CARE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 9044235183     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.95     Document Type: Article

References (22)

1. Holmes F, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
2. Reichman BS, Seidman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
3. Vermorken JB, Huizing MT, Liefting AJM, et al: High-dose Taxol (HDT) with G-CSF in patients with advanced breast cancer (ABC) refractory to anthracycline (ANT) therapy. Eur J Cancer 29A:83, 1993 (suppl 6, abstr 435)
4. Nabholtz JM, Gelmon K, Bontenbal M, et al: Randomized trial of two doses of Taxol in metastatic breast cancer. Proc Am Soc Clin Oncol 12:60, 1993 (abstr 42)
5. Lopes NM, Adams EG, Pitts TW, et al: Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993
6. ®) in human tumour cell lines. Br J Cancer 68:1104-1109, 1993
7. Wilson WH, Berg S, Bryant GB, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/ II study of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994
8. Fisherman JS, McCabe M, Noone MH, et al: Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients wilh metastatic breast cancer. Monogr Natl Cancer Inst 15:189-194, 1993
9. Berg SL, Cowan KH, Balis FM, et al: Pharmacokinetics of Taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 86:143-145, 1994
10. Frei E III, Teicher BA, Cucchi CA, et al: Resistance to alkylating agents: Basic studies and therapeutic implications, in Woolley P III, Tew K (eds): Mechanisms of Drug Resistance in Neoplastic Cells. New York, NY, Academic, 1988, pp 69-87
11. Dimitrov N, Anderson S, Fisher B, et al: Dose intensification and increased total dose of adjuvant chemotherapy for breast cancer: Findings from NSABP B-22. Proc Am Soc Clin Oncol 13:64, 1994 (abstr 58)
12. Rose WC: Taxol: A review of its preclinical in vivo antitumor activity. Anticancer Drugs 3:311-321, 1992
13. Goldspiel BR, Kohler DR, Koustenis AG, et al: Paclitaxel administration using portable infusion pumps. J Clin Oncol 11:2287-2288, 1993
14. Hornung RL, Longo DL: Hematopoietic stem cell depletion by restorative growth factor regimens during repeated high-dose cyclophosphamide therapy. Blood 80:77-83, 1992
15. Watanabe T, Miya T, Fukutomi T, et al: Phase I study of high-dose epirubicin (Epi) and cyclophosphamide (CPA) with rG-CSF for metastatic breast cancer. Proc Am Soc Clin Oncol 11:88, 1992 (abstr 178)
16. Araujo CE, Tessler J: Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (Mesna) to patients with inoperable lung cancer. Eur J Cancer Clin Oncol 19:195-201, 1983
17. Goren MP: Oral Mesna: A review. Semin Oncol 19:65-72, 1992
18. Goldberg MA, Antin JH, Guinan EC, et al: Cyclophosphamide cardiotoxicity: An analysis of dosing as a risk factor. Blood 68:1114-1118, 1986
19. Kennedy MJ, Armstrong D, Donehower R, et al: The hematologie toxicity of the Taxol/cytoxan doublet is sequence dependent. Proc Am Soc Clin Oncol 13:137, 1994 (abstr 342)
20. ®) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6:25-31, 1994
21. Investigators Brochure: Taxol (paclitaxel). Princeton, NJ, Bristol-Meyers Squibb, August 1, 1994
22. Chin A, Ramakrishnan RR, Yoshimura NN, et al: Paclitaxel stability and compatibility in polyolefin containers. Ann Pharmacother 28:35-36, 1994